
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Overactive bladder (OAB)【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:67
Ibrutinib for the treatment of Chronic Lymphatic Leukemia【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:310
Afatinib can be used to treat Non Small Cell Lung Cancer.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:214
Tragliptin is suitable for type 2 diabetes.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:226
Fezolinetant is indicated for the treatment of vasomotor symptoms due to menopause.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:364
STIVARGA is indicated for the treatment of patients with metastatic colorectal cancer (CRC).【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:328
Tofacitinib is indicated for the treatment of adult patients with rheumatoid arthritis.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:345
Used in combination with other antihypertensive drugs for the treatment of hypertension.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:284
Used for treating advanced renal cell carcinoma following failure of a prior systemic therapy.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:307
Applicable to von Hippel-Lindau (VHL) disease patients requiring treatment for renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastoma, or pancreatic neuroendocri···【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:345
Capivasertib is suitable for the treatment of adult patients with specific types of breast cancer.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:253
Sunitinib is a Broad-spectrum antitumor agents.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:246
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:8542025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:10542024-09-07
Recently, Lao Lucius Pharmaceutical (Lucius Pharmaceuticals) issued a solemn statement regarding cou···【more】
Recommended:3462026-10-10
Lucius Pharmaceuticals Version of Vibegron Now Available1.Basic Drug InformationVibegron (generic na···【more】
Recommended:4202026-06-08
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed cou···【more】
Recommended:6192026-05-08
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic drugs from Laos hav···【more】
Recommended:6042026-04-08
Lucius Pharmaceuticals version of Ibrutinib is now availableIn a randomized controlled trial of 269 ···【more】
Recommended:4752026-03-08
Leveraging the WTO patent waiver for least-developed countries (extended to 2033), Laos has seen rap···【more】
Recommended:6222026-31-07

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643